OVERVIEW

Harnessing Immuno-Oncology for the Management of Genitourinary Cancers: How to Optimize Checkpoint Inhibitor Therapy Based on Pathways, Patterns of Response, and Immune-related AEs is organized by Paradigm Medical Communications, LLC and will be held from Jul 10, 2018 - Jul 10, 2019.

Target Audience
This activity has been designed to meet the educational needs of community medical oncologists and advanced practitioners, such as nurse practitioners, PAs, and pharmacists, treating genitourinary (GU) cancers, including renal cell carcinoma and bladder cancer. This activity may also benefit other oncology healthcare professionals involved in the management of patients with renal cell carcinoma and bladder cancer.

Physician Credit Designation Statement
Paradigm Medical Communications, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit.

Pharmacist Accreditation and Designation Statement
This program is approved for 1.0 hours (0.10 CEUS) of continuing pharmacy education credit.

Statement of Need
To provide high-quality, evidence-based care, oncologists must be familiar with the principles of immunology as they relate to the mechanisms of action of immune checkpoint inhibitors as well as the clinical profiles of these agents (as monotherapy or combination therapy) and their roles and patterns of response in first- and subsequent-line treatment of GU cancers, including bladder cancer and renal cell carcinoma. This activity will educate clinicians how to appropriately integrate immune checkpoint inhibitors into clinical practice for treatment of patients with GU cancers.

Learning Objectives
Upon proper completion of this activity, participants should be better able to:
• Describe the principles of immunology as they relate to the mechanisms of action and pathways of immune checkpoint inhibitors in the treatment of genitourinary cancers, including renal cell and bladder cancer.
• Incorporate the latest efficacy data and clinical profiles of new and emerging immune checkpoint inhibitors into optimal management decisions, including recognition of patterns of response, in patients with genitourinary cancer, including renal cell and bladder cancer.
• Evaluate approaches to manage immune-related adverse effects associated with immune checkpoint inhibitors in patients with genitourinary cancer, including renal cell and bladder cancer.